Veru’s obe­si­ty drug rough­ly as safe as We­govy; Keros’ board fight

Last month
News Briefing

A new dawn for psy­che­delics? Com­pass could be the first to find out

Last month
Pharma
In Focus

Post-Hoc Live: Is biotech sen­ti­ment re­al­ly as bad as it seems? 

Last month
Financing
Deals

Strand Ther­a­peu­tics re­ports promis­ing start for mR­NA can­cer ther­a­py

Last month
R&D

Up­dat­ed: MD An­der­son-al­lied in­vest­ment firm tar­gets $250M for sec­ond can­cer biotech fund

Last month
Financing
Startups

In­flaRx cans Go­hibic de­vel­op­ment af­ter skin dis­ease tri­al stopped for fu­til­i­ty

Last month
R&D

Ax­some and Het­ero set­tle patent fight over sleep dis­or­der drug

Last month
Pharma
Law

No­var­tis won bid­ding war for kid­ney drug as Reg­u­lus' top three ex­ecs ex­pect to make over $100M com­bined

Last month
Deals

FDA lead­er­ship preps for sum­mer bio­phar­ma lis­ten­ing tour across six cities

Last month
FDA+

FDA re­jects Savara’s rare lung dis­ease drug over lim­it­ed man­u­fac­tur­ing da­ta

Last month
Pharma
FDA+

Ser­no­va chair re­signs fol­low­ing in­sid­er trad­ing in­dict­ment over No­var­tis-Chi­nook deal

Last month
People
Law

Bound­less Bio changes plans for can­cer drug af­ter tox­i­c­i­ty is­sues

Last month
People
R&D

RFK Jr. ends an­nu­al Covid vac­cine rec­om­men­da­tions for kids, preg­nant women

Last month
FDA+

Lil­ly to buy non-opi­oid pain biotech SiteOne for up to $1B

Last month
Deals
Pharma

Liq­uidia wins ap­proval for in­haled hy­per­ten­sion drug in two set­tings, fur­ther­ing ri­val­ry with Unit­ed Ther­a­peu­tics

Last month
Pharma
FDA+

ITM re­veals up to $262M debt fi­nanc­ing; Caris Life Sci­ences to go pub­lic

Last month
News Briefing

Gil­gamesh’s short-act­ing psy­che­del­ic drug shows rapid ef­fect in Phase 2 de­pres­sion study

Last month
R&D

Bio­gen taps City Ther­a­peu­tics in RNAi deal worth up to $1B

Last month
Startups
Deals

Brook­lyn Health rais­es $6.5M to stan­dard­ize men­tal health as­sess­ment

Last month
Financing
Health Tech

Black­stone's GRIN inks epilep­sy li­cens­ing deal with An­geli­ni, clos­es $140M Se­ries D

Last month
Deals
Pharma

Up­dat­ed: Pa­tient dies in Rock­et gene ther­a­py tri­al, which is put on clin­i­cal hold by FDA

Last month
Cell/Gene Tx
FDA+

Prothena’s amy­loi­do­sis drug flops again, spend­ing and staff cuts are on the way

Last month
People
R&D

In­vestors pump $130M in­to pro­tein de­grad­er start­up Gly­co­Era

Last month
Financing
Startups

Syn­deio de­buts with $90M+ to bring to­geth­er synapse re­pair drugs

Last month
Financing
First page Previous page 14151617181920 Next page Last page
A service from the Financial Times